TCM (4169) reported revenue of NT$62 million for Oct 2026, +10.2% year on year and -0.6% from the previous month. Revenue for Jan–Oct 2026 was NT$602.3 million (+6.3% year on year).
In Oct 2026, it ranked No. 94 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$62 million | +10.2% | -0.6% |
| Sep 2026 | NT$62.4 million | -2.1% | +0.3% |
| Aug 2026 | NT$62.2 million | +21.8% | +0.7% |
| Jul 2026 | NT$61.8 million | +6.7% | -4.7% |
| Jun 2026 | NT$64.8 million | +4.0% | +13.3% |
| May 2026 | NT$57.2 million | -17.2% | -3.3% |
| Apr 2026 | NT$59.1 million | +15.4% | -4.3% |
| Mar 2026 | NT$61.8 million | +9.1% | +34.7% |
| Feb 2026 | NT$45.8 million | -17.6% | -29.7% |
| Jan 2026 | NT$65.3 million | +51.6% | +18.0% |
| Dec 2025 | NT$55.3 million | -20.4% | -12.7% |
| Nov 2025 | NT$63.4 million | +15.4% | +12.6% |
| Oct 2025 | NT$56.3 million | +18.6% | -11.7% |
| Sep 2025 | NT$63.7 million | +28.2% | +24.8% |
| Aug 2025 | NT$51.1 million | -16.9% | -11.8% |
| Jul 2025 | NT$57.9 million | +8.1% | -7.0% |
| Jun 2025 | NT$62.3 million | +29.0% | -9.7% |
| May 2025 | NT$69 million | +22.1% | +34.7% |
| Apr 2025 | NT$51.2 million | -16.3% | -9.5% |
| Mar 2025 | NT$56.6 million | +12.6% | +1.8% |
| Feb 2025 | NT$55.6 million | +35.5% | +29.2% |
| Jan 2025 | NT$43.1 million | -40.7% | -38.1% |
| Dec 2024 | NT$69.5 million | -11.3% | +26.6% |
| Nov 2024 | NT$54.9 million | -44.4% | +15.8% |
| Oct 2024 | NT$47.4 million | -46.1% | -4.5% |
Jan–Oct 2026 cumulative: NT$602.3 million (+6.3% YoY)
Other Biotech & Medical companies
Compare with peers: TCM vs PEC / TCM vs Lotus Pharm / TCM vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16